<![CDATA[Anti-Inflammatory Effects of GLP-1 Medications in Psoriasis and Obesity]]>

Дата публикации: 19-10-2026 12:00:00

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	<![CDATA[GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease]]>	0	8.43	16-10-2026
2	<![CDATA[GLP-1 Candidacy and Prescribing Considerations in Psoriasis]]>	0	10.41	19-10-2026
3	<![CDATA[Securing GLP-1 Access and Exploring Hidradenitis Suppurativa Trials]]>	0	11.63	20-10-2026
4	<![CDATA[Fall Clinical 2026: The Data and Expert Advice Shaping Dermatology Practice]]>	0	13.68	20-10-2026
5	<![CDATA[Nonsteroidal Topicals Guide Special-Site Psoriasis Treatment Decisions]]>	0	16.35	21-10-2026
6	Dispelling Myths Around GLP-1 Medications	0	9.15	24-09-2026
7	GLP-1s: What to Know Beyond Weight Loss	0	7.23	12-10-2026
8	GLP-1s may lower risk for death, heart events among people with hidradenitis suppurativa	5	7	08-07-2026
9	Gastrointestinal Adverse Events Associated With GLP-1 Receptor Agonists Versus DPP-4 Inhibitors in Patients with Type 2 Diabetes: A Multicenter Retrospective Cohort Study	0	16.19	19-10-2026
10	Association Between GLP-1 Receptor Agonist Use and Postpartum Pelvic Complications: A Global Matched Cohort Study	0	14.76	20-08-2026

Классификация: Мнения. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.38. Источник: www.dermatologytimes.com.